To date, no randomized trial has prospectively evaluated ApoB, LDL-particle number, sd-LDL, or HDL efflux capacity as primary endpoints in HF patients receiving SGLT2 inhibitors, representing a major knowledge gap. The gene discussed is APOB; the disease is hydrops fetalis.